Chris Ryan / iStockphoto.com
A jury has said that Flexus Biosciences, a company owned by Bristol-Myers Squibb (BMS), does not need to pay damages despite being liable for trade secrets misappropriation.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Bristol-Myers Squibb, Flexus Biosciences, Incyte, trade secrets misappropriation, jury trial, ICO-1, oncology, cancer research and development